Cited by 933Metabolism, Diabetes, and CancerDiabetes Treatment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Open access

Bowker, Samantha L., Majumdar, Sumit R., Veugelers, Paul, Johnson, Jeffrey A.·2006·Diabetes Care

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—Numerous studies have identified an increased risk of cancer in type 2 diabetes. We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer. RESEARCH DESIGN AND METHODS—This was a population-based cohort study using administrative databases from Saskatchewan Health. Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users. Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score. All statistical tests were two-sided. RESULTS—We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 ± 1.9 years (means ± SD). The mean age for the cohort was 63.4 ± 13.3 years, and 55% were men. Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin. After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1–1.6]; P = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5–2.4; P < 0.0001). CONCLUSIONS—Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin. It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diacare.29.02.06.dc05-1558

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Metformin
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,694
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
A chronic disease score from automated pharmacy data
Korff, M. V., Wagner, E. H., & Saunders, K. W. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 962
Insulin and colon cancer
Giovannucci, E. L. (1995) · Cancer Causes & Control · doi:10.1007/bf00052777 · Cited by 808
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747
Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citation
Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420

Show all 37 references

Sorted by citations

Items 201–300 of 933

The Insulin Receptor: A New Target for Cancer Therapy
Malaguarnera, R., & Belfiore, A. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00093 · Cited by 98
Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis
Singh, S., Singh, H., Singh, P. P., Murad, M. H., & Limburg, P. J. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0429 · Cited by 97
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Marrone, K. A., Zhou, X. C., Forde, P. M., Purtell, M., Brahmer, J. R., Hann, C. L., Kelly, R. J., Coleman, B., Gabrielson, E. W., Rosner, G. L., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0465 · Cited by 99
Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase‐9 activation through a calcium and protein kinase Cα‐dependent pathway: phorbol‐12‐myristate‐13‐acetate‐induced/extracellular signal‐regulated kinase/activator protein‐1
Hwang, Y. P., & Jeong, H. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00762.x · Cited by 97
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy
Phoenix, K. N., Vumbaca, F., Fox, M. M., Evans, R., & Claffey, K. P. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0647-z · Cited by 94
Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 100
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial
Hadad, S. M., Coates, P. J., Jordan, L. B., Dowling, R. J. O., Chang, M. C., Done, S. J., Purdie, C. A., Goodwin, P. J., Stambolic, V., Moulder-Thompson, S. L., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3307-5 · Cited by 97
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
Blin, P., Lassalle, R., Dureau‐Pournin, C., Ambrosino, B., Bernard, M., Abouelfath, A., Gin, H., Jeunne, C. L., Pariente, A., Droz‐Perroteau, C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2429-5 · Cited by 94
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 94
The complexities of obesity and diabetes with the development and progression of pancreatic cancer
Bao, B., Wang, Z., Li, Y., Kong, D., Ali, S. S., Banerjee, S., Ahmad, A., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.11.003 · Cited by 94
Risk of Malignant Neoplasms of Liver and Biliary Tract in Diabetic Patients With Different Age and Sex Stratifications
Chen, H.-F., Chen, P., & Li, C. (2010) · Hepatology · doi:10.1002/hep.23641 · Cited by 93
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation
Gong, Y., Ma, Y., Sinyuk, M., Loganathan, S. N., Thompson, R. C., Sarkaria, J. N., Chen, W., Lathia, J. D., Mobley, B. C., Clark, S. W., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov096 · Cited by 93
Insulin-Sensitizing Therapy Attenuates Type 2 Diabetes–Mediated Mammary Tumor Progression
Fierz, Y., Novosyadlyy, R., Vijayakumar, A., Yakar, S., & LeRoith, D. (2009) · Diabetes · doi:10.2337/db09-1291 · Cited by 92
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort
Baur, D. M., Klotsche, J., Hamnvik, O. R., Sievers, C., Pieper, L., Wïttchen, H., Stalla, G. K., Schmid, R. M., Kales, S. N., & Mantzoros, C. S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.09.012 · Cited by 90
Type 2 Diabetes and Cancer: What Is the Connection?
Cannata, D., Fierz, Y., Vijayakumar, A., & LeRoith, D. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20167 · Cited by 94
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation
Sprynski, A. C., Hose, D., Kassambara, A., Vincent, L., Jourdan, M., Rossi, J., Goldschmidt, H., & Klein, B. (2010) · Leukemia · doi:10.1038/leu.2010.192 · Cited by 93
comoR: a software for disease comorbidity risk assessment
Moni, M. A., & Lió, P. (2014) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-4-8 · Cited by 87
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors
Onitilo, A. A., Engel, J. M., Glurich, I., Stankowski, R. V., Williams, G. M., & Doi, S. A. R. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9971-4 · Cited by 92
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients
Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., & Grassi, G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01480.x · Cited by 87
Use of sulphonylurea and cancer in type 2 diabetes—The Hong Kong Diabetes Registry
Yang, X., So, W. Y., Ronald, C. W., Yu, L. W., Ko, G. T. C., Kong, A. P. S., Ng, V., Luk, A. O. Y., Ozaki, R., Tong, P. C. Y., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.022 · Cited by 88
Old wine in new bottles: Drug repurposing in oncology
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172784 · Cited by 91
Metformin Inhibits Aromatase via an Extracellular Signal-Regulated Kinase-Mediated Pathway
Rice, S., Pellatt, L. J., Ramanathan, K., Whitehead, S. A., & Mason, H. D. (2009) · Endocrinology · doi:10.1210/en.2009-0540 · Cited by 88
Metformin and Cancer: Solutions to a Real-World Evidence Failure
Yu, O. H. Y., & Suissa, S. (2023) · Diabetes Care · doi:10.2337/dci22-0047 · Cited by 92
Mitogenic action of insulin: friend, foe or ‘frenemy’?
Draznin, B. (2009) · Diabetologia · doi:10.1007/s00125-009-1558-6 · Cited by 87
Systematic review and meta-analysis of insulin therapy and risk of cancer
Janghorbani, M., Dehghani, M., & Salehi-Marzijarani, M. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0112-z · Cited by 86
Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells
Li, W., Yuan, Y., Huang, L., Qiao, M.-M., & Zhang, Y. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.028 · Cited by 87
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Diabetes mellitus: new drugs for a new epidemic
Nicholson, G., & Hall, G. M. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer120 · Cited by 84
Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts
Kisfalvi, K., Moro, A., Sinnett‐Smith, J. W., Eibl, G., & Rozengurt, E. (2013) · Pancreas · doi:10.1097/mpa.0b013e31827aec40 · Cited by 86
Clinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 85
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma
Zhou, Y.-Y., Zhu, G.-Q., Liu, T., Zheng, J.-N., Cheng, Z., Zou, T.-T., Braddock, M., Fu, S.-W., & Zheng, M.-H. (2016) · Scientific Reports · doi:10.1038/srep33743 · Cited by 69
Management of pancreatogenic diabetes: challenges and solutions
Makuc, J. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99701 · Cited by 84
Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells
Tosca, L., Ramé, C., Chabrolle, C., Tesseraud, S., & Dupont, J. (2009) · Reproduction · doi:10.1530/rep-09-0351 · Cited by 86
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer
Baba, Y., Nosho, K., Shima, K., Meyerhardt, J. A., Chan, A. T., Engelman, J. A., Cantley, L. C., Loda, M. F., Giovannucci, E. L., Fuchs, C. S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605846 · Cited by 86
Metabolic Profiles Associated With Metformin Efficacy in Cancer
Andrzejewski, S., Siegel, P. M., & St‐Pierre, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00372 · Cited by 85
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer
Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81
Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species
Kajiwara, C., Kusaka, Y., Kimura, S., Yamaguchi, T., Nanjo, Y., Ishii, Y., Udono, H., Standiford, T. J., & Tateda, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700474 · Cited by 83
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
Feng, Y., Velázquez-Torres, G., Gully, C., Chen, J., Lee, M., & Yeung, S. J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01083.x · Cited by 85
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 87
The effect of metformin on apoptosis in a breast cancer presurgical trial
Cazzaniga, M. E., DeCensi, A., Pruneri, G., Puntoni, M., Bottiglieri, L., Varricchio, C., Guerrieri‐Gonzaga, A., Gentilini, O., Pagani, G., Dell’Orto, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.657 · Cited by 81
Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects
Yoon, H., Cho, H., Yoo, H., Kim, S., & Lee, Y. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9460-z · Cited by 81
Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies
Wotton, C. J., Yeates, D., & Goldacre, M. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1987-2 · Cited by 81
Nutrition, metabolic factors and cancer risk
Dossus, L., & Kaaks, R. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.08.003 · Cited by 82
Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection
Kawaguchi, T., Taniguchi, E., Morita, Y., Shirachi, M., Tateishi, I., Nagata, E., & Sata, M. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02191.x · Cited by 78
Metformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 80
Insulin, insulin-like growth factors, insulin resistance, and neoplasia
Pollak, M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.820s · Cited by 78
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer
Lu, Y., Rodríguez, L. A. G., Malgerud, L., González‐Pérez, A., Martín‐Pérez, M., Lagergren, J., & Bexelius, T. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.353 · Cited by 81
AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/β-Catenin Signaling Activity
Kwan, H., Chan, D. W., Cai, P. C. H., Mak, C. S. L., Yung, M. M. H., Leung, T. H. Y., Wong, O. G., Cheung, A., & Ngan, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053597 · Cited by 81
Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
Tossetta, G., & Marzioni, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175503 · Cited by 81
Cancer incidence among patients treated with antidiabetic pharmacotherapy
Oliveria, S. A., Koro, C. E., Yood, M. U., & Sowell, M. O. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.11.002 · Cited by 78
Breast Cancer Chemoprevention: Old and New Approaches
Cazzaniga, M., & Bonanni, B. (2012) · BioMed Research International · doi:10.1155/2012/985620 · Cited by 82
Energy Homeostasis and Cancer Prevention: The AMP-Activated Protein Kinase
Fay, J. R., Steele, V. E., & Crowell, J. A. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0166 · Cited by 77
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kalinsky, K. M., Crew, K. D., Refice, S., Xiao, T., Wang, A., Feldman, S. M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H. H., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.889706 · Cited by 79
Metformin for cancer and aging prevention: is it a time to make the long story short?
Anisimov, V. N. (2015) · Oncotarget · doi:10.18632/oncotarget.6347 · Cited by 77
Insulin in the Adjuvant Breast Cancer Setting: A Novel Therapeutic Target for Lifestyle and Pharmacologic Interventions?
Goodwin, P. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7132 · Cited by 77
Exploiting tumor metabolism: challenges for clinical translation
Heiden, M. G. V. (2013) · Journal of Clinical Investigation · doi:10.1172/jci72391 · Cited by 79
Diabetes and Breast Cancer Subtypes
Bronsveld, H. K., Jensen, V., Vahl, P., Bruin, M. L. D., Cornelissen, S., Sanders, J., Auvinen, A. P., Haukka, J. K., Andersen, M. T., Vestergaard, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170084 · Cited by 76
Interplay between cancer cell cycle and metabolism: Challenges, targets and therapeutic opportunities
Roy, D., Sheng, G. Y., Semukunzi, H., de Carvalho, E. L., Mahanty, A., Yuan, S., & Sun, L. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.019 · Cited by 76
Insulin and cancer: a tangled web
Leitner, B. P., Siebel, S., Akingbesote, N. D., Zhang, X., & Perry, R. J. (2022) · Biochemical Journal · doi:10.1042/bcj20210134 · Cited by 79
Molecular mechanisms of tumor suppression by LKB1
Vaahtomeri, K., & Mäkelä, T. P. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.034 · Cited by 78
Metformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75
Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells
Saito, T., Chiba, T., Yuki, K., Zen, Y., Oshima, M., Koide, S., Motoyama, T., Ogasawara, S., Suzuki, E., Ooka, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070010 · Cited by 75
Diabetes and Cancer
Chowdhury, T. A. (2010) · QJM · doi:10.1093/qjmed/hcq149 · Cited by 76
Insulin, Insulin Resistance, Obesity, and Cancer
Gallagher, E. J., & LeRoith, D. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0101-y · Cited by 76
Diabetes mellitus, hyperglycaemia and cancer
Simon, D., & Balkau, B. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.04.001 · Cited by 74
The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project
Cleveland, R. J., North, K. E., Stevens, J., Teitelbaum, S. L., Neugut, A. I., & Gammon, M. D. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9989-7 · Cited by 74
Role of Metformin in Suppressing 1,2-Dimethylhydrazine-Induced Colon Cancer in Diabetic and Non-Diabetic Mice: Effect on Tumor Angiogenesis and Cell Proliferation
Zaafar, D. K., Zaitone, S. A., & Moustafa, Y. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100562 · Cited by 76
Retracted
Antidiabetic Drug Metformin Suppresses Endotoxin-Induced Uveitis in Rats
Kalariya, N. M., Shoeb, M., Ansari, N. H., Sk, S., & Ramana, K. V. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9432 · Cited by 74
Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer
Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Schernthaner, G.-H., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12412 · Cited by 73
Real-world evidence: the devil is in the detail
Gokhale, M., Stürmer‎, T., & Buse, J. B. (2020) · Diabetologia · doi:10.1007/s00125-020-05217-1 · Cited by 76
Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo
Cai, X., Hu, X., Cai, B., Wang, Q., LI, Y., Tan, X., HU, H., CHEN, X., Huang, J., Cheng, J., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2718 · Cited by 73
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin
Wysocki, P. J., & Wierusz‐Wysocka, B. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.22 · Cited by 73
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
Rico, M., Baglioni, M. V., Bondarenko, M., Laluce, N. C., Rozados, V. R., André, N., Carré, M., Scharovsky, O. G., & Menacho-Márquez, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13760 · Cited by 73
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 77
Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin
Donadon, V., Balbi, M., Casarin, P., Vario, A., & Alberti, A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5695 · Cited by 72
Relationships between cancer and aging: a multilevel approach
Anisimov, V. N., Sikora, E., & Pawelec, G. (2009) · Biogerontology · doi:10.1007/s10522-008-9209-8 · Cited by 73
Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer
Beauchamp, M.-C., Yasmeen, A., Knafo, A., & Gotlieb, W. H. (2010) · Journal of Oncology · doi:10.1155/2010/257058 · Cited by 73
Caveolin‐1 is essential for metformin inhibitory effect on IGF1 action in non‐small‐cell lung cancer cells
Salani, B., Maffioli, S., Hamoudane, M., Parodi, A., Ravera, S., Passalacqua, M., Alama, A., Nhiri, M., Cordera, R., & Maggi, D. C. (2011) · The FASEB Journal · doi:10.1096/fj.11-192088 · Cited by 74
Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan
Tseng, C. (2010) · Gut · doi:10.1136/gut.2010.226522 · Cited by 71
Risk of Cancer in Diabetes: The Effect of Metformin
Malek, M., Aghili, R., Emami, Z., & Khamseh, M. E. (2013) · ISRN Endocrinology · doi:10.1155/2013/636927 · Cited by 73
Old drug, new trick: Repurposing metformin for gynecologic cancers?
Febbraro, T., Lengyel, E. R., & Romero, I. L. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.011 · Cited by 71
Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update
Bhattamisra, S. K., Siang, T. C., Rong, C. Y., Annan, N. C., Sean, E. H. Y., Xi, L. W., Lyn, O. S., Liew, H. S., Choudhury, H., Pandey, M., et al. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190115145702 · Cited by 73
The Mechanism of Action of Biguanides: New Answers to a Complex Question
Magno, L. D., Pastena, F. D., Bordone, R., Coni, S., & Canettieri, G. (2022) · Cancers · doi:10.3390/cancers14133220 · Cited by 81
Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation
Yunn, N.-O., Koh, A., Han, S., Lim, J. H., Park, S., Lee, J., Kim, E., Jang, S. K., Berggren, P., & Ryu, S. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv767 · Cited by 69
Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4
Cheng, G., & Lanza‐Jacoby, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.118 · Cited by 69
Long‐term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study
Kim, Y., Kim, S., Cho, S., Park, J., Choi, I. J., Lee, Y. J., Lee, E. K., Kook, M., Kim, C. G., Ryu, K. W., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12660 · Cited by 70
Metformin as an antitumor agent in cancer prevention and treatment
Li, D. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00119.x · Cited by 68
The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer
Ferguson, R. D., Gallagher, E. J., Scheinman, E. J., Damouni, R., & LeRoith, D. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00010-1 · Cited by 72
Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation?
Sharif, A. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03550.x · Cited by 69
Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes
Yang, X., So, W. Y., Ronald, C. W., Kong, A. P. S., Lee, H. M., Yu, L. W. L., Chow, C., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2010) · Diabetes Care · doi:10.2337/dc10-1509 · Cited by 68
Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications
Pinthus, J. H., Whelan, K. F., Gallino, D., Lu, J., & Rothschild, N. (2011) · Canadian Urological Association Journal · doi:10.5489/cuaj.10196 · Cited by 70
A review of lifestyle and environment risk factors for pancreatic cancer
Zanini, S., Renzi, S., Limongi, A. R., Bellavite, P., Giovinazzo, F., & Bermano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.040 · Cited by 67
Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
Tossetta, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112893 · Cited by 68
Diabetes and Thyroid Cancer Risk: Literature Review
Shih, S., Chiu, W., Chang, T., & Tseng, C. (2012) · Experimental Diabetes Research · doi:10.1155/2012/578285 · Cited by 67
New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
Zadra, G., Priolo, C., Patnaik, A., & Loda, M. F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1955 · Cited by 69
Overview of metformin: special focus on metformin extended release
Ali, S., & Fonseca, V. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.705829 · Cited by 67
Diabetes mellitus and metformin in hepatocellular carcinoma
Fujita, K., Iwama, H., Miyoshi, H., Tani, J., Oura, K., Tadokoro, T., Sakamoto, T., Nomura, T., Morishita, A., Yoneyama, H., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i27.6100 · Cited by 68
Diabetes mellitus: influences on cancer risk
Szablewski, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2573 · Cited by 69
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?
Malaguarnera, R., Vella, V., Nicolosi, M. L., & Belfiore, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00314 · Cited by 68

Authors: Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A.
Affiliations: University of Alberta (CA)
ORCID: Majumdar, Sumit R.
Veugelers, Paul
Johnson, Jeffrey A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2006-02-01
Volume: 29
Issue: 2
Pages: 254-258
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.29.02.06.dc05-1558
OpenAlex: W2156370651
Cited by: 933
References: 37
Citations by year: 2026: 9 · 2025: 13 · 2024: 28 · 2023: 32 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 45 · 2016: 43 · 2015: 52 · 2014: 55 · 2013: 96 · 2012: 93
FWCI: 16.30
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: type 2 diabetes, cancer mortality, sulfonylureas, insulin therapy, metformin, antidiabetic drugs, cancer risk
MeSH terms: Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Retrospective Studies, Risk Factors, Saskatchewan, Severity of Illness Index, Sulfonylurea Compounds, Cohort Studies, Comorbidity, Multivariate Analysis, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks